Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shensong Yangxin capsule plus dronedarone after ablation for persistent atrial fibrillation
ChiCTR2500096575Phase 4Not yet recruiting
- Sponsor
- Sichuan Mianyang 404 Hospital
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial in Atrial fibrillation (AFib) comparing Shensong Yangxin capsule + dronedarone with Dronedarone alone (2 arms). Primary endpoints: 1-year recurrence rate of atrial fibrillation after radiofrequency ablation and Complications within 30 days after ablation. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
shensong yangxin capsuledronedarone
03
Conditions
Atrial fibrillation (AFib)
Beyond the preview
Go deeper on ChiCTR2500096575.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500096575.